Ribavirin and interferon∝-2b combination therapy for 48 weeks in patients with chronic hepatitis C who either failed (non-responder) or relapsed (relapsers) from previous interferon monotherapy.

被引：0
|
作者：
Tsai, NC
Coste, A
Shimoda, N
Yee, H
Jao, R
Wong, L
Buto, S
Shimoda, S
机构：
[1] Univ Hawaii, Honolulu, HI 96822 USA
[2] St Francis Med Ctr, Honolulu, HI USA
[3] Univ Hawaii, Honolulu, HI 96822 USA
来源：
HEPATOLOGY | 1999年 / 30卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
429
引用
收藏
页码：268A / 268A
页数：1
相关论文
共 50 条
  • [41] Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic hepatitis C virus-infected nonresponders and relapsers after interferon alfa-2a monotherapy.
    Wietzke-Braun, P
    Meier, V
    Braun, F
    Ramadori, G
    HEPATOLOGY, 2000, 32 (04) : 353A - 353A
  • [42] Evaluation of initial biochemical and virological responses to induction therapy with interferon-A2B in combination with ribavirin and ketoprofen for non-responder patients with chronic hepatitis C.
    Munoz, AE
    Levi, D
    Miguez, C
    Cisterna, D
    Terg, R
    HEPATOLOGY, 2000, 32 (04) : 554A - 554A
  • [43] Racial differences in response to Interferon and Ribavarin +/- Ketoprofen in patients with chronic hepatitis C who have previously failed interferon monotherapy.
    Brown, A
    Nunes, F
    Santoro, J
    Kaufman, B
    Gasic, A
    Matusow, G
    Schultz, C
    Chu, J
    Brass, CA
    Lucey, RM
    GASTROENTEROLOGY, 2000, 118 (04) : A949 - A949
  • [44] Interferon alpha plus ribavirin tor chronic hepatitis C genotype 1b non-responder patients to interferon alone.
    Iacono, OL
    Castro, A
    Diago, M
    Cors, R
    Borque, MJ
    Buey, LG
    Monzon, CG
    Pedreira, J
    Otero, RM
    HEPATOLOGY, 1999, 30 (04) : 266A - 266A
  • [45] Prediction of response to retreatment with interferon alfa 2B in chronic hepatitis C patients who previously failed 24 weeks of interferon alpha therapy.
    Tong, M
    Blatt, LM
    Tong, L
    Sayadzadeh, K
    Conrad, A
    GASTROENTEROLOGY, 1998, 114 (04) : A1355 - A1355
  • [46] Interferon Alpha 2b in Combination with Ribavirin as a Treatment for Chronic Hepatitis C
    Mandokhel, Sherbet Khan
    Aziz-U-Rehman
    Khan, Mohammad Saleem
    Azeemullah
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2011, 5 (01): : 168 - 171
  • [47] Pegylated interferon alfa 2b and ribavirin for hepatitis C patients who were nonresponders to previous
    Lawitz, EJ
    Bala, NS
    Becker, S
    Brown, G
    Davis, M
    Dhar, R
    Ganeshappa, KP
    Gordon, S
    Holtzmuller, K
    Jeffries, M
    Li, JJ
    Monsour, H
    Nader, P
    Rosenfield, T
    Tolman, K
    Kadakia, S
    GASTROENTEROLOGY, 2003, 124 (04) : A783 - A784
  • [48] Double-blind placebo controlled study of interferon versus interferon plus ribavirin for the treatment of hepatitis C in patients who previously failed interferon monotherapy.
    Nunes, DP
    Anastopoulos, H
    Gordon, F
    Chopra, S
    Petruff, C
    Salomons, H
    Wilson, S
    Afdhal, NH
    HEPATOLOGY, 1999, 30 (04) : 199A - 199A
  • [49] PEG-interferon α-2b plus ribavirin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained virologic response following interferon A or interferon α-2b plus ribavirin therapy.
    Sulkowski, M
    Rothstein, KD
    Stein, L
    Godofsky, E
    Shoultz, D
    Hudnall, R
    Huff, M
    Dieterich, D
    HEPATOLOGY, 2001, 34 (04) : 419A - 419A
  • [50] Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to prior therapy with either interferon alfa and ribavirin or pegylated interferon and ribavirin
    Chen, K
    Seraphin, P
    Murphy, L
    Shah, N
    HEPATOLOGY, 2005, 42 (04) : 670A - 670A
12345